NCT04398745 - A Study of Belantamab Mafodotin Monotherapy in Multiple Myeloma Participants With Normal and Varying Degree of Impaired Renal Function | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 9, 2020

Primary Completion Date

April 21, 2025

Study Completion Date

December 31, 2025

Conditions

Multiple Myeloma

Interventions

DRUG

Belantamab mafodotin

Belantamab mafodotin will be provided as lyophilized powder which will be available as 100 milligrams per vial (mg/vial) in single-use vial for reconstitution. Lyophilized belantamab mafodotin will reconstituted using water for injection, dilute with normal 0.9 % saline before use.

Trial Locations (19)

10676

GSK Investigational Site, Athens

11528

GSK Investigational Site, Athens

21565

GSK Investigational Site, Incheon

27514

GSK Investigational Site, Chapel Hill

33322

GSK Investigational Site, Plantation

49241

GSK Investigational Site, Busan

60611

GSK Investigational Site, Chicago

66205

GSK Investigational Site, Westwood

77380

GSK Investigational Site, The Woodlands

85724

GSK Investigational Site, Tucson

90211

GSK Investigational Site, Beverly Hills

95817

GSK Investigational Site, Sacramento

97239

GSK Investigational Site, Portland

119228

GSK Investigational Site, Singapore

169856

GSK Investigational Site, Singapore

32224-3899

GSK Investigational Site, Jacksonville

21201-1595

GSK Investigational Site, Baltimore

06351

GSK Investigational Site, Seoul

06591

GSK Investigational Site, Seoul